Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
54 hedge funds and large institutions have $38M invested in Aevi Genomic Medicine Inc in 2015 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 19 increasing their positions, 6 reducing their positions, and 10 closing their positions.
217% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 6
110% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 10
26% more funds holding
Funds holding: 43 → 54 (+11)
17% less capital invested
Capital invested by funds: $45.8M → $38M (-$7.87M)
22% less call options, than puts
Call options by funds: $62K | Put options by funds: $79K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.11M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.55M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$827K |
| 4 |
State Street
Boston,
Massachusetts
|
+$713K |
| 5 |
BC
Broadfin Capital
New York
|
+$689K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$2.26M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.41M |
| 3 |
PA
Perceptive Advisors
New York
|
-$1.35M |
| 4 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$338K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$314K |
GNMX Hedge Fund Activity: Q2 2015 in Review
54 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q2 2015, worth a combined $38M — down 17% from $45.8M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new GNMX positions and 10 closed out — a net gain of 11 holders — while 19 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $3.11M. The largest seller was Jennison Associates, cutting an estimated $2.26M.
- 54 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q2 2015, up from 43 in Q1 2015.
- Funds reported $38M of Aevi Genomic Medicine Inc stock for Q2 2015, down 17% quarter-over-quarter.
- 21 funds opened new Aevi Genomic Medicine Inc positions in Q2 2015 and 10 closed out, a net change of +11 holders.
- The largest Aevi Genomic Medicine Inc buyer in Q2 2015 was BlackRock Fund Advisors, an estimated $3.11M added.
- The largest Aevi Genomic Medicine Inc seller in Q2 2015 was Jennison Associates, an estimated $2.26M sold.
Based on aggregated 13F filings for Q2 2015.